HBM Healthcare increases stake in ADARx Pharmaceuticals through IPO

ADARx Pharmaceuticals completed its IPO at $17 a share and began trading on Nasdaq on 25 September. HBM invested an additional $15.3 million in the offering, taking its total investment to $19.3 million and valuing its stake at $25.4 million.